Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.

Recursion Pharmaceuticals, which currently operates a leading AI supercomputer and a proprietary OS for in silico drug discovery, remains pre-commercial with no products on the market or phase-3 assets despite partnerships with Merck and Roche, leaving its strategy unproven and the stock risky. Eli Lilly, by contrast, is building an AI supercomputer that will surpass Recursion's and combines that initiative with an established revenue-generating portfolio (notably leadership in the weight-loss market) and extensive clinical-trial data, making it the safer way for investors to gain exposure to AI-driven drug discovery.

Analysis

Market structure: Large-cap pharm (LLY) stands to capture disproportionate share of AI-driven discovery budgets as it can absorb GPU/compute capex, proprietary clinical data, and regulatory costs; small-cap platform players like RXRX face commoditization risk and funding squeeze. Expect 12–36 month reallocation of 5–15% of early discovery R&D spend toward incumbent pharma partners, supporting NVDA/AMD demand for datacenter GPUs and lifting semis/energy consumption in near term.

Risk assessment: Tail risks include regulatory guidance constraining AI-derived INDs, a major RXRX clinical failure that could trigger >50% drawdown, or a GPU supply shock that raises capex by 20–40%. Immediate (days) impacts are volatility spikes in RXRX options; short-term (3–12 months) hinges on upcoming readouts and LLY supercomputer commissioning; long-term (2–5 years) outcomes depend on demonstrable drug approvals and data/IP access.

Trade implications: Favor large-cap pharma exposure and optionality on AI upside while shorting high-volatility pre-commercial names. Use relative-value (long LLY, short RXRX) to hedge biology risk; options should be used to express asymmetric payoff—LEAP call spreads for LLY, time-limited puts for RXRX around clinical catalysts. Rotate portfolio +5% into big-pharma and semis (NVDA) while trimming small-cap biotech by 3–5%.

Contrarian angles: Consensus underestimates data/label quality and clinical translational risk — compute alone won’t buy approvals; this makes RXRX a binary, high-gamma bet that may be oversold by >30% ahead of positive readouts. Conversely, LLY’s advantage may be overstated if data-sharing, IP limits, or model generalizability issues surface; watch licensing terms and trial outcomes as inflection points.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Eli Lilly (LLY) via a 12–18 month call spread (buy ATM LEAP, sell ~+25% strike) to limit cost; target +25–40% in 12 months, cut if LLY falls >12% from entry or misses near-term revenue/weight-loss guidance.
• Initiate a tactical 0.75–1.5% short exposure to Recursion (RXRX) funded with 6–9 month puts (5–10% OTM) if a material clinical readout is scheduled within 3–6 months; cap loss at 50% per tranche and cover on any positive Phase 2 signal.
• Execute a pair trade: long LLY vs short RXRX at a 2:1 dollar ratio to express asymmetric, hedged thesis; rebalance monthly and unwind the pair if RXRX posts a Phase 2 success or LLY announces an AI licensing deal >=$200M upfront.
• Overweight large-cap pharma by +5% vs benchmark (add LLY, PFE, MRK) and increase exposure to NVDA/AMD by 1–2% to capture GPU demand; reduce small-cap pre-commercial biotech exposure by 3–5% and reassess on major regulatory or clinical catalysts within 12 months.